Janssen registers Phase 3 TRIlogy-6 trial in newly diagnosed multiple myeloma
Janssen Research & Development listed a Phase 3 study comparing ramantamig plus daratumumab against a standard four-drug regimen with transplant in transplant-eligible patients.
One new registry entry was posted for Janssen this week.
- Janssen registered a Phase 3 trial, "TRIlogy-6" (NCT07903272), comparing Ramantamig and Daratumumab (Ramantamig-D) against Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) followed by autologous stem cell transplant and Daratumumab and Lenalidomide maintenance in participants with newly diagnosed multiple myeloma who are transplant eligible.1 The study is sponsored by Janssen Research & Development, LLC, with European Myeloma Network B.V. as a collaborator,1 and is not yet recruiting, with an estimated start date of 2026-12-14 and estimated primary completion of 2037-01-11.1 The trial plans to enroll a combined total of 1000 participants across the two sponsors, with J&J enrolling 325 and EMN enrolling 675.1 The primary outcome is progression-free survival, defined as the time from randomization to confirmed progressive disease or death, measured up to approximately 10 years.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.